QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.000836v1 33/4/500    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhu, M. Articles by Mitroka, J. Search for Related Content PubMed PubMed Citation Articles by Zhu, M. Articles by Mitroka, J.

CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

Pharmaceutical Candidate Optimization (M.Z., W.Z., H.J., D.Z., S.Y., R.D., J.M.), and Clinical Discovery (N.V.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

This study was carried out to determine the metabolic pathways of buspirone and cytochrome P450 (P450) isoform(s) responsible for buspirone metabolism in human liver microsomes (HLMs). Buspirone mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-oxidation on the piperazine ring to buspirone N-oxide (Bu N-oxide), and hydroxylation to 3'-hydroxybuspirone (3'-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6'-hydroxybuspirone (6'-OH-Bu) in HLMs. The apparent K_m values for buspirone metabolite formation in pooled HLMs were 8.7 (1-PP), 34.0 (Bu N-oxide), 4.3 (3'-OH-Bu), 11.4/514 (5-OH-Bu), and 8.8 µM (6'-OH-Bu). CYP3A inhibitor ketoconazole (1 µM) completely inhibited the formation of all major metabolites in HLMs (0-16% of control), whereas the chemical inhibitor selective to other P450 isoforms had little or no inhibitory effect. Recombinant CYP3A4, CYP3A5, and CYP2D6 exhibited buspirone oxidation activities among nine P450 isoforms tested. The overall metabolism rate of 5 µM buspirone by CYP3A4 was 18-fold greater than that by CYP2D6 and 35-fold greater than that by CYP3A5. In a panel of HLMs from 16 donors, buspirone metabolism correlated well CYP3A activity (r² = 0.85-0.96, < 0.0005), but not the activities of other P450 isoforms. The metabolism rates of buspirone in CYP2D6 poor-metabolizer genotype HLMs were comparable to those in pooled HLMs. Taken together, these data suggest that CYP3A, mostly likely CYP3A4, is primarily responsible for the metabolism of buspirone in HLMs.

This article has been cited by other articles:

				K. Minato, R. Suzuki, A. Asagarasu, T. Matsui, and M. Sato Biotransformation of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a Novel 5-Hydroxytryptamine (5-HT)1A Agonist/5-HT3 Antagonist, in Human Hepatic Cytochrome P450 Enzymes Drug Metab. Dispos., May 1, 2008; 36(5): 831 - 840. [Abstract] [Full Text] [PDF]

				H. Wong, R. C. Dockens, L. Pajor, S. Yeola, J. E. Grace Jr., A. D. Stark, R. A. Taub, F. D. Yocca, R. C. Zaczek, and Y.-W. Li 6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats Drug Metab. Dispos., August 1, 2007; 35(8): 1387 - 1392. [Abstract] [Full Text] [PDF]

				R. C. Dockens, D. E. Salazar, I. E. Fulmor, M. Wehling, M. E. Arnold, and R. Croop Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J. Clin. Pharmacol., November 1, 2006; 46(11): 1308 - 1312. [Abstract] [Full Text] [PDF]